Maura Lianne Gillison, M.D., Ph.D.

 

Co-Investigator, Projects 5 and 6

                                                                                          

Current Appointments:

 

Assistant Professor of Oncology

The Johns Hopkins University School of Medicine

 

Joint Appointment in Epidemiology,

The Johns Hopkins Bloomberg School of Public Health

 

Active Staff, Oncology

The Johns Hopkins Hospital

 

Contact Information:

 

The Bunting-Blaustein Cancer Research Bldg.

1650 Orleans Street, Rm. G91

Baltimore, Maryland 21231-1000

Ph:  (410) 502-7412

Fax: (410) 614-9334

E-mail: gillima@jhmi.edu

 

        

Education and Training:

 

         

                           B.S., 1987

Duke University, Durham, NC, Zoology

 

M.D., 1991

The Johns Hopkins University School of Medicine, Baltimore, MD

 

Postdoctoral fellow, 1991-1992

The Johns Hopkins Hospital, Baltimore, MD, Department of Medicine, Division of Hematology, laboratory of Chi Van Dang, M.D., Ph.D.

 

Medical Resident, 1993-1995

Massachusetts General Hospital, Medical Services, Boston, MA

 

Clinical Fellow in Oncology, 1996-1998

The Johns Hopkins Oncology Center, Baltimore, MD

 

Senior Clinical Fellow in Oncology, 1998-2000

The Johns Hopkins Oncology Center, Baltimore, MD

 

Ph.D., 2001

The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, Clinical Investigation

 

Certifications

 

1996, Internal Medicine 

1999, Medical Oncology  

 

 

Selected Publications:

 

1.      Articles

 

Richards RG, Brown OE, Gillison ML, and Sedwick WD. Drug concentration dependent DNA lesions are induced by the lipid soluble antifolate, piritrexim (BW301U). Molec. Pharm. 1986; 30: 651-658.

 

Dang CV, Dolde C, Gillison ML, and Kato GJ. Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins. Proc. Natl. Acad. Sci. USA 1992; 89: 599-602

 

Fearon ER, Finkel T, Gillison ML, Kennedy SP, Casella JF, Tomaselli GF, Morrow JS, and Dang CV. Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells. Proc. Natl. Acad. Sci. USA 1992; 89: 7958-7962.

 

4.      Gillison ML, Koch WM, Capone RB, Spafford M, Westra W, Wu L, Zuhurak M L, Daniel, RW, Symer DE, Shah KV, and Sidransky D.  Evidence for a causal association between Human Papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute 2000; 92:709-20.

 

Capone RB, Pai SI, Koch WM, Gillison ML, Nowroz Danish H, Westra WH, Daniel R, Shah KV, Sidransky D. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clinical Cancer Research 2000; 6: 4171-4175.

 

Ha PK, Pai SI, Westra WH, Gillison ML, Tong BC, Sidransky D, Califano JA.  Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity.  Clin Cancer Res. 2002; 8(5):1203-9.

 

Begum S, Gillison ML, Ansari-Lari M, Shah K, Westra WH.  Detection of Human Papillomavirus in cervical lymph nodes:  A highly effective strategy for localizing site of tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clinical Cancer Research 2003; 9(17): 6469-75.

 

Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison ML, Pardoll D, Wu L, and Wu TC. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003;21, 4036-4042.

 

Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Shah KV, Gillison ML.  Oral Human Papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. Journal of Infectious Diseases 2004; 189(4): 686-698.

 

Kreimer AR, Viscidi R, Alberg AJ, Daniel R, Gravitt PE, Shah KV, Gillison ML.  Gender differences in sexual behaviors associated with HPV-16, 18 and 33 seroprevalence.  Sexually Transmitted Diseases 2004; 31(4): 247-256.

 

Gillison ML, O’Reilly S, Noe DA, Donehower RC, and Grochow LB.  A pharmacokinetic and pharmacodynamic study of trimetrexate administered to cancer patients with renal or hepatic impairment. Cancer Therapeutics. (In Press).

 

Reviews

 

Gillison ML and Ambinder RF. Human herpesvirus-8. Curr. Opin. Oncol. 1997; 9:440-449.

 

Gillison ML, Koch WM, and Shah KV. Human papillomavirus and squamous cell carcinoma of the head and neck: are some head and neck cancers a sexually transmitted disease? Curr. Opin. Oncol. 1999; 11:191-199.

 

Gillison ML and Forastiere A.  Laryngeal preservation: a discussion of the National Comprehensive Cancer Center treatment guidelines.  Hematology Oncology Clinics of North America 1999; 13:699-718.

 

Gillison ML and KV Shah. Human papillomavirus associated head and neck squamous cell carcinoma: mounting evidence of an etiologic role for HPV in a subset of head and neck cancers. Curr. Opin. Oncol. 2001; 13:183-188.

 

Devaraj K, Gillison ML, Wu T-C. Development of HPV vaccines for HPV-associated          head and neck squamous cell carcinoma. Crit. Rev. Oral Biol. Med. 2003; 14(5):345-362.

 

Gillison ML. Human papillomavirus associated head and neck cancer is a distinct clinical, epidemiological and molecular entity. Seminars in Oncology 2004 (In Press).

              

  

 
 

 

 

 

Project 6

 

 

Investigators

 

T.-C. Wu

Debbie Armstrong

Maura Gillison

Martin Pomper

Chien-Fu Hung

 

Personnel

 

Ya-Chea Tsai

Irena Tartokovsky

Caroline Fidyk

 

 

 

 

 

Copyright © 2004 The Johns Hopkins University. All rights reserved.